Aytu BioPharma Net Income

The latest net income for AYTU is $-14M as of June 2026. That compares with $-14M in the prior-year period — down 5.1% year over year. That is below the Healthcare sector average of $16B. Investors often review this figure alongside Aytu BioPharma's historical trend and sector peers before judging valuation or financial health.

Over the past year, AYTU's net income moved from $-14M to $-14M — a 5.1% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Aytu BioPharma's operating scale or balance-sheet position.

Against Healthcare companies, AYTU currently prints $-14M for net income, while the sector average sits near $16B. That is roughly 100.1% below the sector mean. Large gaps often invite a closer look at Aytu BioPharma's growth, margins, and balance sheet.

A net income figure of $-14M for AYTU is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $16B. Explore the charts below for those layers of context.

After noting AYTU's net income ($-14M), review year-over-year change from $-14M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.